From BioSpectrumAsia, January 31:
New investment comes three months after Mesh Bio secured historic regulatory approval
Mesh Bio, a Singapore-based health deep tech startup transforming chronic disease management through predictive analytics, has raised $3.5 million in Series A financing led by East Ventures, a pioneering and leading sector-agnostic venture capital firm focusing on Southeast Asia. This round of investment also saw participation of Elev8, Seed Capitals, and other existing shareholders.
The funding will allow Mesh Bio to offer its digital twin technologies to healthcare providers and scale the deployment of these solutions across Hong Kong and Southeast Asia, mainly Indonesia and the Philippines....
....MUCH MORE
This stuff is happening now. And even though long-time readers have probably internalized the quotes on models, don't let them stop you from thinking about how useful a digital model twin could be.
And for newer readers here's a post from 2012 (there are earlier uses but this was the first that popped up):
Modelling vs. Science
If an experiment is not reproducible it is not science.
If an hypothesis is not falsifiable it is not science.
Finally, our two guiding principles regarding models:
From Pannell Discussions: